Journal Club articles to be reviewed: 

1). Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. 

DOI: https://doi.org/10.1200/JCO.2017.74.2940.

2). Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

http://dx.doi.org/10.1016/S1470-2045(18)30365-6